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Schistosoma mansoni, one of the causative agents of schistosomiasis, has a complex life cycle infecting over 200 million people
worldwide. Such a successful and proliﬁc parasite life cycle has been shown to be dependent on the adaptive interaction between
theparasiteandhosts.Tyrosinekinases(TKs)playakeyroleinsignalingpathwaysasdemonstratedbyalargebody ofexperimental
work in eukaryotes. Furthermore, comparative genomics have allowed the identiﬁcation of TK homologs and provided insights
into the functional role of TKs in several biological systems. Finally, TK structural biology has provided a rational basis for
obtainingselective inhibitorsdirected to thetreatmentofhumandiseases.Thispaper covers theimportantaspects ofthephospho-
tyrosine signaling network in S. mansoni, Caenorhabditis elegans, and humans, the main process of functional diversiﬁcation of
TKs, that is, protein-domain shuﬄing, and also discusses TKs as targets for the development of new anti-schistosomedrugs.
1.Introduction
Blood ﬂukes of the genus Schistosoma (Platyhelminthes:
Trematoda) are the causative agents of schistosomiasis living
in the bloodstream of their ﬁnal hosts. Over 200 million
people are infected worldwide and about 700 million live
in endemic regions, with more than 90% of the cases of
infection occurring in sub-Saharan Africa [1, 2].
Schistosomes have a complex developmental cycle with
diverse life stages remarkably well adapted to their environ-
ment and hosts. Such a successful and proliﬁc schistosome
life cycle has been shown to be dependent on the adaptive
molecular “dialogue” that takes place between the para-
site and the host [3]. The contact of the parasite with
host signals (e.g., hormones, growth factors, etc.) could
control cell proliferation and diﬀerentiation processes in
schistosomes [4]. Inthis context,diverse molecularpathways
dependentonkinase-mediatedsignalinghavebeendescribed
in schistosomes and shown to be involved in host-parasite
relationships [5].
Kinases play key roles in a broad range of cellular pro-
cesses. The molecular phylogeny of the protein kinases upon
which KinBase was developed [6] was ﬁrst described by
Hanks et al. [7]. In this classiﬁcation scheme, the protein
kinase superfamily is split into two groups: eukaryotic pro-
tein kinases (ePKs) and atypical protein kinases (aPKs). The
former constitutes one of the largest and most important
protein families in eukaryotes, accounting for ∼2% of the
total proteins identiﬁed in a variety of genomes [8]. The
ePKs are further divided into nine groups (TK, AGC,
CaMK, CMGC, CK1, STE, RGC, TKL, and other) based on
sequence similarity of their catalytic domains, the presence
of accessory domains, and their modes of regulation [6].
By phosphorylating substrate proteins, kinases modify
theactivity,location,and aﬃnitiesofupto30%ofall cellular2 Journal of Signal Transduction
Table 1: Protein tyrosine kinase classiﬁcation. Tyrosine kinases
classiﬁed into ePK groups, families, and subfamilies followed the
proposed hierarchy described elsewhere [7–9]. RTK: receptor tyro-
sine kinase.CTK: cytoplasmic tyrosine kinase.
Type Abbreviation Family name
RTK Alk Anaplastic lymphoma kinase
Axl Also known as TAM (Tyro3, Axl, Mer) after
the three human members
CCK4 Colon carcinoma Kinase 4
DDR Discoidin domain receptor kinase
EGFR Epidermal growth factor receptor
Eph Ephrin receptor
FGFR Fibroblast growth factor receptor
InR Insulin Receptor
Met MET or MNNG HOS transforminggene
MUSK Muscle-speciﬁc kinase
PDGFR Platelet-derived growth factor receptor
Ret Ret proto-oncogene
ROR RAR-related orphan receptor
Tie Tyrosine kinase with immunoglobulin-like
and EGF-like domains
VEGFR Vascular endothelial growth factor receptor
VKR Venus ﬂytrap kinase receptor
CTK Abl Abelson murine leukemia homolog
Ack Activated Cdc42-associated tyrosine kinase
Csk Src subgroup kinase which phosphorylates
Src
Fak Focal adhesion kinase
Fer Fps/Fes related
Jak Janus kinase
Lmr Lemur kinase
Ryk Rich protein kinase
Sev
Named after Drosophila sevenless,a receptor
tyrosine kinase involved in eye cell fate
determination
Src v-Src sarcoma viral oncogene homolog
Syc Syc protein
Tec Tec protein tyrosine kinase
Trk Trk protein kinase
proteins and direct most cellular processes, particularly in
signal transduction and coordination of complex pathways
[8]. Many of these pathways are highly conserved among
eukaryotes with 53 distinct kinase functions, which are con-
servedamong yeasts, nematodes, insects, and vertebrates [8].
Multicellular life demands complex activities such as
cell proliferation, diﬀerentiation, adhesion, and motility
to be precisely controlled. Many of these processes are
in fact regulated by protein tyrosine kinases (TKs). The
tyrosine phosphorylation occurs viathe covalent addition of
a phosphate group from ATP or GTP to tyrosine residues
in a variety of proteins, and the emergence of this signaling
mechanism was likely a key enabling event in the transition
to multicellularity [10].
T h et y r o s i n ek i n a s ec o m p r i s e sc e l ls u r f a c er e c e p t o r
(RTK)and nonreceptororcytosolic (CTK)kinases, classiﬁed
into29families (Table 1).Deregulationofthetyrosine kinase
activity by various mechanisms leading to gain or loss of
function have been observed in a large number of tyrosine
kinases and shown to be associated with diﬀerent human
diseases [11]. Due to their central regulatory roles, tyrosine
kinases are consideredinteresting targetsforthe treatment of
various diseases, most prominently cancer [12].
Recently, the draft genome of S. mansoni was published
[13] and large-scale transcriptome projects have provided
detailed information for the identiﬁcation of protein kinases
[14]. The ePK complement of S. mansoni,d e ﬁ n e da st h e
ePKinome, consists of 252 ePKs in the predicted proteome,
representing 1.9% of the total proteins encoded the parasite
genome [15]. Only 16 S. mansoni ePKs were experimentally
studied, with 10 belonging to the TK group [16, 17].
The tyrosine kinases represent thefourth largestgroup of
the S. mansoni ePKinome including 15RTKs and 19CTKs,
classiﬁed into 18 families [15]. Of the parasite RTKs, 10 have
homologs in six distinct human protein families, two belong
toVenuskinasereceptorfamily[18,19],alsopresentinmany
insects, and three were not grouped into families previously
described in metazoans. At the moment, several tyrosine
kinases characterized in S.mansoni are described as potential
targets for therapy against schistosomiasis.
Tyrosine kinases constitute the largest group of ePKs in
Caenorhabditis elegans, with 92 members, which represent
21% of all ePKs encoded in the nematode genome [20]. In
C. elegans, these proteins correspond to 40RTKs and 52
CTKs. The RTKs include 16 members of the worm-speciﬁc
KIN-15-family, 13RTKs with orthologs representing 10 of
the 20 families of human RTKs, and 11RTKs that remain
unclassiﬁed with no identiﬁable mammalian counterpart
[20].
T h eF e rf a m i l yi st h el a r g e s ti nC. elegans,w i t h3 7m e m -
bers. Only a single member, SmFes, was observed in S.
mansoni (Table 2). Furthermore, immunolocalization assays
showed that SmFes is particularly expressed at the terebra-
torium of miracidia, an organ that helps the penetration of
the parasite in the snail host, and tegument of cercaria and
schistosomula skin stage [4]. These ﬁndings suggest that
SmFes may play a role in signal transduction pathways
involved in larval transformation after penetration into
intermediate and deﬁnitive hosts [4, 15].
Ninety unique tyrosine kinase genes, representing ∼17%
of all ePKs, were identiﬁed in the human genome, along with
nine pseudogenes [9, 21]. There were 58 RTKs distributed
into 20 families and 32 CTKs grouped into 10 families [21].
Humans contain 14 members of Eph family, while only
as i n g l em e m b e r( S m p139480) was identiﬁed in S. mansoni
(Table 2). Eph receptor signaling is responsible for the most
diverse set of biological events performed by any tyrosine
kinaseincludingorgandevelopment,tissueremodeling,neu-
ronal signaling and insulin secretion, and bone metabolism
[16]. The S. mansoni Eph functional role remains unknown.
H e r e ,w ed i s c u s st h ed i v e r s i t yo ft h eS. mansoni tyrosine
kinases from the functional and evolutionary perspectives.Journal of Signal Transduction 3
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Figure 1: S. mansoni phosphotyrosine-signaling network. In the phosphotyrosine signaling pathway, the tyrosine kinase (TK), phosphoty-
rosinephosphatase(PTP),and Src Homology2 (SH2) domainsforma highlyinterdependent signalingnetwork. At the moment,81protein
members of the phosphotyrosine signaling network on S. mansoni genome were identiﬁed. This signaling network serves as the “writer”,
“eraser”, and “reader” domains,respectively, for processing phosphotyrosine targets.
This review is organized in three main sections: phospho-
tyrosine signaling network, tyrosine kinase functional diver-
siﬁcation, and tyrosine kinases as new anti-schistosome drug
targets.
2.Phosphotyrosine Signaling Network
The cellular signaling machinery mediated by tyrosine kin-
ases is widely studied in modern metazoans [22]. In these
organisms phosphotyrosine-signaling pathways are medi-
ated by a “toolkit” of three functional protein domains
(Figure 1): the tyrosine kinase catalytic domain (TK) that
phosphorylates-speciﬁc target tyrosine residues, the phos-
photyrosine-phosphatase domain (PTP) that removes the
phosphates, and the Src Homology 2 domain (SH2) that
recognize these modiﬁcations [23]. Together, these domains
form the “writer,” “eraser,” and “reader” domains that is
common to many diverse cellular information processes
[24]. All members of phosphotyrosine network are found in
S. mansoni.
Phosphotyrosine-binding (PTB) domains also partici-
pate in tyrosine kinase-signaling networks (not included in
Figure 1). According to the S. mansoni relational database,
SchistoDB (www.schistodb.net) [14], there are two genes,
Smp 139400 and Smp 126500, that code for proteins with
signiﬁcant similarity to the PTB domain (PF08416) as
deﬁned by the Pfam database [25]. The S. mansoni PTB
domains are members of the Tensin cytoplasmic phospho-
protein (Tec) family. PTB domains are underrepresented in
the S. mansoni genome when compared to the 37 proteins
with SH2 domains (Figure 1,“ reader”). There are nine
tyrosine kinases among theSH2-containingdomain proteins
Table 2: Distribution of some tyrosine kinase families in S. man-
soni, C. elegans, and human. S. mansoni tyrosine kinases were clas-
siﬁed according to KinBase [6] by combining sequence similarity
searches (HMMs) and phylogenetic analysis [15]. For comparison,
occurrence of the ePKs families in C. elegans and human is shown.
RTK: receptor tyrosine kinase. CTK: cytoplasmic tyrosine kinase.
(See the list of abbreviations for the respective family full name).
Type Family S. mansoni C. elegans H. sapiens
RTK CCK4 1 0 1
EGFR 4 1 4
Eph 1 1 14
InsR 2 1 3
Musk 1 0 1
Ror 1 1 2
VKR 2 0 0
CTK Abl 2 1 2
Ack 2 2 2
Csk 1 1 2
Fak 1 0 2
Fer 1 37 2
Ryk 1 1 1
Sev 1 1 1
Src 6 3 11
SYK 2 0 2
Tec 1 0 5
Trk 1 1 3
in S. mansoni. The remaining ones are tensin, suppressors of
cytokinesignaling, Tysuppressors,RhoGTPase, RasGTPase,
and adaptor proteins.4 Journal of Signal Transduction
Analysis of the C. elegans genome has indicated 11 PTB
domain proteins related to the phosphotyrosine-binding
activity [26]. Similar to S. mansoni,t h eP T Bd o m a i ni sr e l -
atively underrepresented when compared to the 57 proteins
with SH2 domains encoded in the C. elegans genome [27].
There are nearly 60 PTB domain proteins in humans
[28], six of which have been reported to carry muta-
tions that contribute to inherited human diseases such as
familial stroke, hypercholesteremia, coronary artery dis-
ease, Alzheimer’s disease, and diabetes [24]. These ﬁndings
demonstrated that these proteins play an important role in
organizing signaling complexes in a broad range of physio-
logical processes [24]. PTB domains also bind head groups
of acidic phospholipids consistent with the nearly exclusive
subcellular localization of PTB domains to the membrane or
juxtamembrane regions, suggesting that most PTB domains
are multifunctional [29]. Similar to S. mansoni and C.
elegans, the PTB domain is relatively underrepresented when
compared to the 110 proteins with SH2 domains encoded in
the human genome.
The number ofPTB domain proteinsisgreater in human
than in S. mansoni and C. elegans proteomes [20]. In ad-
dition, among the 946 PTB domain proteins deposited in
SMART [30], eight are found in echinoderms, 28 in nema-
todes, 58 in arthropods, and 852 in chordates. These data
suggest higher levels of diversity of the vertebrate PTB
domains in relation to invertebrates.
Searching the S. mansoni relational database, SchistoDB
[14], for proteins with signiﬁcant similarity to the tyro-
sine phosphatase sequence domain (PF00102) (Figure 1,
“eraser”) as deﬁned by Finn et al. [25], there are 18 genes
potentially encoding tyrosine phosphatases in this parasite.
T h en u m b e ro ft y r o s i n ek i n a s ee n c o d i n gg e n e s( 3 4p r o -
teins) in the S. mansoni genome is higher than that of
tyrosine phosphatases, which suggests that these enzymes
may act ondiﬀerent substrates. However,we should consider
the following observations: (1) among the 34 S. mansoni
tyrosine kinases, four are predicted to be catalytically inac-
t i v e ,w h i l et h en u m b e ro fi n a c t i v et y r o s i n ep h o s p h a t a s e si s
notknown atthemoment; (2)thereare eightgenesencoding
members of the dual speciﬁcity phosphatase family, which
can dephosphorylate both phosphotyrosine and phospho-
serine or phosphothreonine residues within one substrate;
(3) the S. mansoni genomic data remains fragmented and
much work is still necessary to complete the assembly of the
genome sequences [31]. Therefore, the number of tyrosine
phosphatases may be underestimated in the actual assembly
and annotation of the S. mansoni genome.
Analysis of the C. elegans genome identiﬁed 91 tyrosine
phosphatase genes [32]. Generally, worms contain a similar
number of tyrosine kinases and phosphatases. This coordi-
nateexpansion inthenematodelineagecouldpossiblyreﬂect
the biological need to maintain a tight regulation of the
phosphotyrosine process.
The human genome encodes 107 tyrosine phosphatase
family members [33], which together exceed the number
tyrosine kinases in the same organism [8]. However,
a more detailed inspection reveals that only 81 proteins
are active phosphatases with the ability to dephosphorylate
phosphotyrosine residues. The remaining phosphatases are
catalytically inactive (11 proteins), dephosphorylate mRNAs
(two proteins), or dephosphorylate inositol phospholipids
(13 proteins). Out of the 90 human tyrosine kinases, 85 are
believed to be catalytically active leading to similar numbers
of active tyrosine phosphatases and kinases in humans.
Furthermore, both enzyme types display comparable
patterns of tissue distribution [33].
Recently,thecrucialroleoftyrosine phosphorylation was
shown in snail-schistosome interactions [34]. The exposure
of miracidia to the haemolymph of schistosome-susceptible
snails is followed by increased protein tyrosine phosphory-
lation proﬁle. In addition, the treatment of miracidia with a
tyrosine kinase-speciﬁc inhibitor signiﬁcantly impaired their
development into primary sporocysts. These results suggest
the participation of signal transduction pathways mediated
by tyrosine kinases during the snail-host infection and
transformation of the evolutionary stages of the S. mansoni
life cycle.
Schistosoma proteins SmTK3 (Smp 054500) and SmTK5
(Smp 136300) are Src family members, while SmTK4 (Smp
149460) belongs to the Syk family. The later is present in
reproductive organs and it is possibly involved in the devel-
opment of gonads and oogenesis [36, 37].
Detailed knowledge of the signaling pathways that con-
trol schistosome growth, metabolism, diﬀerentiation and
survival is of particular interest because only mature adult
worms produce eggs, which are responsible for disease pa-
thology.
3.Tyrosine KinaseFunctionalDiversiﬁcation
A simple way to assess molecular diversity of gene/protein
families is to analyze their domain organization [38, 39].
The functional diversity of the S. mansoni tyrosine kinases
is reﬂected by the presence of 14 distinct accessory domains
besides the catalytic domain that is found in all ePKs
(Figure 2). Following the tyrosine kinase catalytic domain,
the two most frequently occurring protein domains in the S.
mansoni tyrosine kinases are Src Homology 2 (SH2) and Src
Homology 3 (SH3) domains.
Important cluesregarding therelationships betweenSH2
and SH3domainsare providedbythe genomesofunicellular
eukaryotes, which lack the complete set of phosphotyrosine
signaling machinery [26].
The genome of a simple unicellular eukaryote like the
budding yeast, Saccharomyces cerevisiae shows one proto-
SH2 domain, which shares similarity with the SH2 domain
from other organisms but, does not show the phosphoty-
rosine-binding activity [40]. Although SH2 is not present
in prokaryotes [41], a variety of SH2-containing tyrosine
kinases have been found in organisms, such as the sponge,
implyingthatmanyofthedomainrearrangementshappened
early in metazoan evolution [30]. Tyrosine phosphorylation
mediates the formation of heteromeric protein complexes
at or near the plasma membrane by acting as a “switch”
to induce the SH2 domain binding as described elsewhere
[30]. The formation of these protein complexes, on the other
hand, is likelyto control the activation ofsignal transductionJournal of Signal Transduction 5
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Figure 2: Representative sequence domain architectures of some S. mansoni TKs belonging to the receptor and nonreceptor members.
Proteinfamilyabbreviationisindicatedontheleftsideofeachproteinarchitecture (seethelistofabbreviationsfortherespective fullnames).
Proteinidentiﬁers(e.g.,Smp 125360)shownaboveeachimagewereretrieved fromSchistoDB[14].Abbreviationsfollowedare: PTK domain
(protein tyrosine kinase catalytic domain), SH2 (Src Homology 2 domain), SH3 (Src Homology 3 domain), PDB (P21-Rho-binding
domain), Ank (ankyrin repeat), Recep L domain (receptor L domain), Furin-like (furin-like cysteine rich region), ANF recep (receptor
familyligand-binding region),Ephrin Ibd (ephrin receptor ligand-binding domain),andBTK (Bruton’styrosine kinasemotif).The protein
domain architectures were generated using DOG 1.0 [35] based on the domain limits Pfam [25].6 Journal of Signal Transduction
pathways by tyrosine kinases. Thus, the SH2 domain serves
as the prototype for a growing family of protein-interaction
domains, characteristic of polypeptides involved in signal
transduction pathways. Together with the SH2 domain, the
SH3 may modulate interactions with the cytoskeleton and
membrane.
The SH2 domain is present in eight S. mansoni tyrosine
k i n a s e sg r o u p e di n t of o u rC T Kf a m i l i e s :C s k ,F e r ,S c r ,S y k ,
and Tec (Figure 2). Members of Scr and Syk families have
been characterized and are involved in organizing the
cytoskeleton in the parasite gonads [42] and germ cell devel-
opment [37].
The six SH3-containing domain tyrosine kinases in S.
mansoni are present in three CTK families: Csk, Syk, and Tec
(Figure 2). Members of Csk and Syk families have the SH3
domain in addition to SH2 and the tyrosine kinase catalytic
domains. In addition to these domains, members of the
Tec family contain two other domains: Bruton’s tyrosine
kinase (BTK) and Pleckstrin homology (PH) domains.
Similar domain architecture is observed in the Tec family
of the choanoﬂagellate, Monosiga brevicollis.C u r r e n t l y ,M.
brevicollis is the only unicellular organism that presents
a tyrosine kinase signalling network that has been either
characterized experimentally or identiﬁed by computational
prediction [26].
An alternative way to investigate functional diversiﬁca-
tion of proteins and protein families is through phyloge-
nomics (“intersection between phylogenetics and genomics”)
as previously proposed [43]. This evolutionary framework,
originally designed to improve functional prediction of un-
characterized genes/proteins, has been applied to a broad
range of studies [43, 44].
The relationships among 23 selected tyrosine kinases
from S. mansoni were inferred by phylogenomic analysis
of their catalytic domain sequence (data not shown). Tree
information corroborates the grouping of these proteins into
distinct families encoded in the parasite genome, such as
EGFR (epidermal growth factor receptor) and VKR (venus
ﬂytrap kinase receptors).
As mentioned before, most of these proteins remain
experimentally uncharacterized. Some of them are proposed
as drug targets, that is, ABL and EGFR family members. The
aforementioned approach could be used as a framework for
hypothesis testing to gain insights into the changes leading
to sequence and functional diversiﬁcation across proteins/
organisms over evolutionary time.
4.Tyrosine KinasesasNew Anti-schistosome
DrugTargets
In the past decades, “a single drug for a single target” para-
digm has dominated drug discovery approaches. A systems-
biology approach, especially focused on the elucidation of
cellular signaling pathways, could provide a framework, for
anti-schistosome drug discovery [45].
Signaling pathways controlled by protein kinases are
a central theme in biological systems. An aberrant protein
kinase activity has been implicated in a variety of human dis-
eases, such as cancer, rheumatoid arthritis, and cardiovascu-
larandneurologicaldisorders[46].Therefore,modulationof
kinase activity represents an attractive therapeutic approach
for human diseases. The design and development of speciﬁc
inhibitors for protein kinases, thus, became a major strategy
in many drug discovery programs [11].
When the focus is the discovery of new drugs against
schistosomiasis it is necessary to answer some key questions:
What is the current need for new drugs against schisto-
somiasis? What are the challenges faced in the process of
ﬁnding drugs? What genes/proteins can be used as potential
chemotherapeutic targets? And ﬁnally, are tyrosine kinases
potential targets for new drugs against Schistosoma species?
The drug Praziquantel (PZQ), for which the detailed
mode of action is still unclear [47], is the only commercially
available treatment for the schistosomiasis. PZQ success as
a drug has contributed to a lack of urgency and investment
in identifying new therapies, either in terms of searching for
chemical entitiesormoleculartargets. However, resistance to
PZQ has been developed in more than one occasion in the
laboratory [48], and the extensive use of PZQ in mass drug
administration programs has raised concern regarding the
selection of drug resistant schistosomes in the ﬁeld [47].
There has been little incentive to invest in the discovery
and development of antitrematode drugs. However, public-
private partnerships have been formed for some of the
neglected tropical diseases. One example of such partnership
is the Drugs for Neglected Diseases Initiative (DNDi), focus-
ing on human African trypanosomiasis and leishmaniasis.
Drug discovery and development programs do not yet exist
for any of the major helminthoses such as schistosomiasis
[49].
By using a comparative chemogenomics approach, Caf-
frey and colleagues have identiﬁed 72 potential target pro-
teins in the S. mansoni predicted proteome [50]. Among the
72 proteins identiﬁed, two are protein kinases grouped into
the GSK and CMGC families. Furthermore, some anticancer
drugs developed to inhibit deregulated protein kinases can
also inhibit schistosome enzymes, thus blocking parasite
development [51].
Polo kinases (Plks) have crucial conserved functions in
controlling the eukaryotic cell cycle through several events
during mitosis [52]. S. mansoni Polo kinase, SmPlk1,
was identiﬁed and characterized [53]. Using the speciﬁc
inhibitor, BI 2536, to block SmPlk1 kinase activity caused
profound alterations in the gonads of both genders, includ-
ing a reduction of gamete production. At present, the dihy-
dropteridinone compound BI 2536 is the most potent and
advanced anti-Plk1 molecule in clinical trials [18].
Eight PK inhibitors with anticancer properties display
activities on schistosomes. Tyrphostins AG 538 and AG 1024
[54]a sw e l la sH N M P A - ( A M )3[ 55] inhibit the tyrosine
kinase of human insulin receptors and were shown to reduce
glucose uptake in schistosomes. Both the TGFβ-R tyro-
sine kinase inhibitor TRIKI and the Src-kinase inhibitor
Herbimycin A reduce mitotic activity and fecundity in
schistosomes in an additive manner [56]. H89, an inhibitor
of the catalytic unit of PKA (PKA-C), induces loss of egg
production and viability in schistosomes [57]. Piceatannol,
an inhibitor of the Syk tyrosine kinase, provokes reductionJournal of Signal Transduction 7
Table 3: EST and SAGEdata of the S.mansoni tyrosine kinases. Protein identiﬁers were retrieved from SchistoDB.[14]. Gene expression was
evaluated in three diﬀerent mammalianhost stages, 3- and 7-day-old schistosomula and adult worms. RTK: receptor tyrosine kinase. CTK:
cytoplasmic tyrosine kinase. Protein families are also indicated. (See the list of abbreviations for the respective family full name).
Type SchistoDB Family 3-day schistosomula 7-day schistosomula Adult worms
EST EST EST SAGE
RTK Smp 173380 CCK4 X X
Smp 093930.2 EGFR X X X
Smp 152680 EGFR X
Smp 165470 EGFR X X
Smp 173590 EGFR X X X
Smp 139480 Eph X
Smp 009990 InsR X X X
Smp 074030 InsR X
Smp 136550 Musk X
Smp 019790 VKR X X X
Smp 153500 VKR X
CTK Smp 169230 Abl X
Smp 128790 Abl X X X
Smp 162900 Ack X X X
Smp 164930 Ack X X
Smp 125360 Csk X X X
Smp 137610 Fak X X
Smp 164810 Fer X X
Smp 006920 Src X
Smp 054500 Src X X
Smp 136300 Src X X X
Smp 027400 SYK X X X
Smp 149460 SYK X X X
Smp 124850 Tec X X
Smp 134800 TRK X
of egg production in treated schistosomes [55]. Imatinib,
an Abl kinase inhibitor, approved by the US Food and
Drug Administration (FDA) and used in the clinic, has fatal
physiological eﬀects on schistosomes in vitro at doses similar
to those used for cancer treatment in humans [51, 58].
TreatmentwithImatinib isgenerallywell tolerated,evenover
a period of many years, with a low incidence of severe side-
eﬀects.
The results obtained using anti c a n c e rd r u g sf o rt r e a t i n g
schistosomiasis suggest that the treatment period using
a kinase inhibitor with schistosome-killing properties will
be signiﬁcantly shorter compared to cancer treatment [51].
However, three main points make it diﬃcult to use kinase
inhibitors as anti-schistosome compound when compared to
PZQ: (1)unlike most kinase inhibitors, PZQ isgenerally well
tolerated; (2) PZQ represents a low-cost medicine, whereas
cancer drugs such as Imatinib are still expensive, and (3)
in particular, protein kinases share very similar structural
and functional features, making it more diﬃcult to design
as p e c i ﬁ ci n h i b i t o r .
Issues regarding the enzyme speciﬁcity may be over-
come by drug redesign guided by the identiﬁcation of
structural features that promote promiscuity and selectivity
ﬁlters that enable target discrimination [59]. Furthermore,
costs could be brought down via generic producers with
expiring patents, which in the case of Imatinib will happen
soon. Second-generation compounds for the same target are
already in the pipeline, and this will have an additional eﬀect
on price reduction [51].
TheuseofTKinhibitorsas chemotherapeuticagentsmay
beextendedtootherhelminth parasites, includingtheﬁlarial
nematode Brugia malayi. Indeed, the genome of this parasite
encodes a total of 205 protein kinases that are potential
drug targets and correspond to about half of the human
complement [60].
Tyrosine kinases have been shown to be essential for
the proliferation and/or viability of clinically relevant schis-
tosome life-cycle stages [53]. Moreover, the available data
concerningtheexpression oftyrosine kinases throughoutthe
life-cycle, which are accessible at SchistoDB [14], show that
a number of these enzymes are expressed in schistosomula
and/oradultworms, thetherapeutictargets.Serialanalysis of
gene expression (SAGE) data shows that 19 tyrosine kinases
are expressed in adult worms (Table 3). On the other hand,8 Journal of Signal Transduction
expressed sequence tag (EST) suggests that 18 are expressed
in adult worms, among which 11 are also expressed by 3-
day old schistosomula and one by 7-day-old schistosomula.
One CTK (Smp 134800) is expressed only in 7-day-old
schistosomula (Table 3). Quantitative real-time PCR assays
arealsonecessarytoverifystagespeciﬁcityoftyrosinekinases
expression. However, TKs expressed in common by adult
worms and schistosomula should probably be preferentially
targeted for drug discovery.
Therefore, tyrosine kinases inhibitors are applicable to
the development of alternative strategies to reduce both pa-
thology and transmission of schistosomiasis [61].
5.Conclusionand FuturePerspectives
Schistosome studies have truly entered a new stage with
the recent publication of the S. mansoni [13, 62]a n dS.
japonicum genomic sequence data [63]. It is now vital to
investigate the functional roles of gene products to answer
questions concerning the fundamental biology of these
important human parasites. As discussed here, tyrosine
kinases, which participate in signaling pathways, are of inter-
est when it comes to understand organisms such as parasites.
Multicellular organisms use a, three-protein domain,
“toolkit” to mediate phosphotyrosine signaling: tyrosine
kinases catalytic (“writer”), tyrosine phosphatase catalytic
(“eraser”), and Src Homology 2 (“reader”) responsible for
phosphotyrosine modiﬁcatio n so fav a r i e t yo fp r o t e i n s[ 39].
Phosphotyrosine signaling is a complex system that exerts
crucial biological eﬀects by regulation of interactions at
the molecular and physiological levels. All members of
phosphotyrosine machinery were found in S. mansoni.T h e
CCK4, FAK, Musk, SYK, and Tec tyrosine kinase families
are found both in S. mansoni and in humans, but not in C.
elegans (Table 2). The VKR family is present neither in C.
elegans nor in humans, nor in the model insect Drosophila
melanogaster [18].Moreover,S.mansoniistheonlyorganism
so far discovered in which more than one representative of
the VKR family is present.
Domainshuﬄinghas beenobservedinseveralorganisms
leading to sequence, structural, and/or functional diversiﬁ-
cation of proteins [64]. The functional diversity observed in
the S. mansoni tyrosine kinases is reﬂected by the presence
and distinct combinations of 14 accessory domains besides
the catalytic domain, which is found in all ePKs described so
far. S. mansoni has a complex life cycle; therefore, acquiring
proteins with new functions is essential for the evolution of
the parasite.
The dependence on a single drug, PZQ, for treating
schistosomiasis and the reports of possible resistance [48]
motivates the search for new drug targets. The design and
development of speciﬁc inhibitors for tyrosine kinases thus
have became a major strategy in many drug discovery pro-
grams [11]. Tyrosine kinases have been shown to be essential
for proliferation and/or viability of parasite life-cycle stages
that are clinically relevant [51]. Therefore, tyrosine kinases
inhibitors are applicable to the development of alternative
strategies to reduce both pathology and transmission of
schistosomiasis.
Combining computational and experimental approaches
of other helminth parasites, whose genome sequencing
projects are underway, should greatly advance our under-
standing on the functional diversity of tyrosine kinases and
the parasite and on the parasite biology and evolution.
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